Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.
Young Kwang Chae, MD, MPH, MBA
Advertisement
Articles by Young Kwang Chae, MD, MPH, MBA
Advertisement
Latest Updated Articles
Dr. Chae on Using Crizotinib to Treat MET+ NSCLCPublished: February 28th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5